Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Expenses incurred under agreements		$ 1,163	$ 1,323
Interest expense	[1]	4,200	3,505
Sumitomo Pharma, Co., Ltd. | Letter Agreement with Sumitomo Dainippon Pharma, Co., Ltd. | Term Loan
Interest expense		$ 3,632	$ 2,904

[1] Includes $3,632 and $2,904 of interest expense under the Sumitomo Pharma Loan Agreement for the three months ended June 30, 2022 and 2021, respectively (see Note 5).